rosuvastatin + BI 1323495

Rosuvastatin + BI 1323495 is a combination of two investigational and approved agents. Rosuvastatin is an FDA-approved statin medication used to lower cholesterol and prevent cardiovascular events by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing clearance of LDL from plasma[3][5][7]. BI 1323495 is an investigational small molecule developed by Boehringer Ingelheim, characterized as an inhibitor of P-glycoprotein (P-gp), organic anion transporting polypeptide 1B1 (OATP1B1), and breast cancer resistance protein (BCRP) in vitro[8]. Clinical trials have evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of this combination in healthy volunteers and patients with non-cystic fibrosis bronchiectasis or for drug-drug interaction studies[2][4][8].